Tumor necrosis factor-α production and disease severity after immunization with enriched major core protein (p26) and/or infection with equine infectious anemia virus

Veterinary Immunology and Immunopathology

Volumn 57, Issue 1-2, 1997, Pages 33-47

  Costa, L R R ^a,e   De Miranda Santos, I K F ^b,d   Issel, C J ^a   Montelaro, R C ^c  

^a UNIVERSITY OF KENTUCKY   (United States)

^b EMBRAPA CERRADOS   (Brazil)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e LOUISIANA STATE UNIVERSITY   (United States)

Author keywords

Equine infectious anemia virus; Inflammatory cytokine; Lentivirus vaccine; Major core protein; Thrombocytopenia; Tumor necrosis factor

Indexed keywords

CORE PROTEIN; TUMOR NECROSIS FACTOR ALPHA; VIRUS VACCINE;

ADOLESCENT; ANEMIA; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; EQUINE INFECTIOUS ANEMIA VIRUS; HORSE; HORSE DISEASE; IMMUNIZATION; INTRAMUSCULAR DRUG ADMINISTRATION; NONHUMAN; THROMBOCYTOPENIA;

ALPHAVIRUS; ANIMALIA; EQUIDAE; EQUINE INFECTIOUS ANEMIA VIRUS; EQUUS CABALLUS; LENTIVIRUS; ORYCTOLAGUS CUNICULUS;

EID: 0030743881     PISSN: 01652427     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-2427(96)05770-4     Document Type: Article

References (51)

1. Allen, G.K., Green, E.M., Robinson, J.A., Garner, H.E., Loch, W.E. and Walsh, D.M., 1993. Serum tumor necrosis factor alpha concentrations and clinical abnormalities in colostrum-fed and colostrum deprived neonatal foals given endotoxin. Am. J. Vet. Res., 54: 1404-1410.
2. Barral-Neto, M., Badaró, R., Barral, A., Almeida, R.P., Santos, S.B., Badaró, F., Pedral-Sampaio, D., Carvalho, E.M., Falcoff, E. and Falcoff, R., 1991. Tumor necrosis factor (cachetin) in human visceral leishmaniasis. J. Infect. Dis., 163: 853-857.
3. Bate, C.A.W. and Kwiatkowski, D.P., 1994. Stimulators of tumor necrosis factor production released by damaged erythrocytes. Immunology, 83: 256-261.
4. Beutler, B., Milsark, I.W. and Cerami, A.C., 1985. Passive immunization against cachetin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science, 229: 869-871.
5. Carpenter, S. and Cheseboro, S., 1989. Change in host cell tropism associated with in vitro replication of equine infectious anemia virus. J. Virol., 83: 2492-2496.
6. Corradin, S.B., Buchmuller-Rouiller, Y. and Mauel, J., 1991. Phagocytosis enhances murine macrophage activation by interpheron-gamma and tumor necrosis factor. Eur. J. Immunol., 21: 2553-2558.
7. Costa, L.R., Issel, C.J., Montelaro, R.C., Cook, S.J., Cook, R.F., Rushlow, K.E., Grund, C. and Wang, S.Z-S., 1995. Responses of ponies to challenge with equine infectious anemia virus following exposure to recombinant gp90 or viral p26 immunogens. Eq. Infect. Dis., 8: 85-94.
8. Crawford, T.B., Cheevers, W.P., Klevjer-Anderson, P. and McGuire, T.C., 1978. Equine Infectious anemia: virion characteristics, virus-cell interaction and host responses. Symp. Mol. Cell. Biol., 11: 727-744. ICN-UCLA.
9. Dinarello, C.A., 1991. Interleukin-1 and interleukin-1 antagonist. Blood, 77: 1627-1652.
10. Ellis, J.A., Russell, H.I. and Du, C.W., 1994. Effect of selected cytokines on the replication of Corynebac-terium pseudotuberculosis and ovine lentiviruses in pulmonary macrophages. Vet. Immunol. Immunopathol., 40: 31-47.
11. Folks, T.M., Clouse, K.A., Justement, J., Rabson, A., Duh, E., Kehrl, J.H. and Fauci, A.D., 1989. Tumor necrosis factor-α induces expression of human immunodeficiency virus in a chronically infected T cell clone. Proc. Natl. Acad. Sci. USA, 86: 2365-2368.
12. Gonzaléz-Amaro, R., Garcïa-Monzón, C., García-Buey, L., Moreno-Otero, R., Alonso, J.L., Yague, E., Pivel, J.P., López-Cabrera, M., Fernández-Ruiz, E. and Sánchez-Madrid, F., 1994. Induction of tumor necrosis factor cc production by human hepatocytes in chronic viral hepatitis. J. Exp. Med., 179: 841-848.
13. Grau, G.E., Piguet, P.-F., Vassalli, P. and Lambert, P.-H., 1989. Tumor necrosis factor and other cytokines in cerebral malaria: experimental and clinical data. Immunol. Rev., 112: 49-70.
14. Grau, G.E., Taylor, T.E., Molyneux, M.E., Wirima, J.J., Vassilli, P., Hommel, M., Lambert, P.-H., 1989. Tumor necrosis factor and disease severity in children with malaria. N. Engl. J. Med., 320: 1586-1591.
15. Griffin, G.E., Leung, K., Folks, T.M., Kunkel, S. and Nabel, G.J., 1989. Activation of HIV gene expression during monocyte differentiation by induction of NF-kappa B. Nature, 339: 70-73.
16. Hu, K.-Q., Yu, C.H. and Vierling, J.M., 1992. Up-regulation of intracellular adhesion molecule 1 transcription by hepatitis B virus X protein. Proc. Natl. Acad. Sci. USA, 89: 1141-1145.
17. Issel, C.J., Horohov, D.W., Lea, D.F., Adams Jr., W.V., Hagius, S.D., McManus, J.M., Allison, A.C. and Montelaro, R.C., 1992. Efficacy of inactivated whole-virus and subunit vaccines in preventing infection and disease caused by equine infection anemia virus. J. Virol., 66: 3398-3408.
18. Karunaweera, N.D., Grau, G.E., Gamage, P., Carter, R. and Mendis, K.M., 1992. Dynamics of fever and serum levels of tumor necrosis factor are closely associated during clinical paroxysms in Plasmodium vivax malaria. Proc. Natl. Acad. Sci. USA, 89: 3200-3203.
19. Kehrl, J.H., Miller, A. and Fauci, A.S., 1987. Effect of tumor necrosis factor alpha on mitogen-activated human B cells. J. Exp. Med., 166: 786-791.
20. Kettelhut, I.C. and Golberg, A.L., 1988. Tumor necrosis factor can induce fever in rats without activating protein breakdown in muscle or lipolysis in adipose tissue. J. Clin. Invest., 81: 1384-1389.
21. Köhler, H., Müller, S. and Nara, P.L., 1994. Deceptive imprinting in the immune response against HIV-1. Immunol. Today, 15: 475-478.
22. Lahdevirta, J., Maury, C.P., Teppo, A.M. and Repo, H., 1988. Elevated levels of circulating cachetin/tumor necrosis factor in patients with acquired immunodeficiency syndrome. Am. J. Med., 85: 289-291.
23. MacKay, R.J., Merrit, A.M., Zertuche, J.-M., Whittington, M. and Skelley, A., 1992. Tumor necrosis factor activity in the circulation of horses given endotoxin. Am. J. Vet. Res., 52: 533-538.
24. MacKay, R.J. and Socher, S.H., 1992. Anti-equine tumor necrosis factor (TNF) activity of antisera raised against human TNF alpha and peptide segments of human TNF-alpha. Am. J. Vet. Res., 53: 921-924.
25. Malmquist, W.A., Barnett, D. and Becvar, C.S., 1973. Production of equine infectious anemia antigen in a persistently infected cell line. Arch. Virol., 42: 361-370.
26. McGuire, W., Hill, A.V.S., Allsopp, C.E.M., Greenwood, B.M. and Kwjatkowski, D., 1994. Variation in the TNF-α promoter region associated with susceptibility to cerebral malaria. Nature, 371: 508-511.
27. Moldawer, L.L., Marano, M.A., Wei, H., Fong, Y., Silen, M.L., Kuo, G., Manogue, K.R., Vlassara, H., Cohen, H., Cerami, A. and Lowry, S.F., 1989. Cachetin/tumor necrosis factor-α alters red blood cell kinetics and induces anemia in vivo. FASEB J., 3: 1637-1643.
28. Montagnier, L., Dauguet, C., Axler, C., Chaumaret, S., Gruest, J., Nugeyre, M.T., Rey, F., Barre-Sinsoussi, F. and Chermann, J.C., 1984. A new type of retrovirus isolated from patients presenting with lymphadenopathy and acquired immune deficiency syndrome: structural and antigenic relatedness with equine infectious anemia virus. Ann. Virol., 135: 199-131.
29. Montelaro, R.C., Parekh, B., Orrego, A. and Issel, C.J., 1984. Antigenic variation during persistent infection by equine infectious anemia virus, a retrovirus. J. Biol. Chem., 259: 10539-10544.
30. Morris, D.D., Crowe, N. and Moore, J.N., 1990. Correlation of clinical and laboratory data with serum tumor necrosis factor activity in horses with experimentally induced endotoxemia. Am. J. Vet. Res., 51: 1935-1940.
31. Morris, D.D. and Moore, J.N., 1991. Tumor necrosis activity in serum from neonatal foals with presumed septicemia. J. Am. Vet. Med. Assoc., 199: 1584-1589.
32. Morris, D.D., Moore, J.N., Crowe, N., 1991. Serum tumor necrosis factor activity in horses with colic attributable to gastrointestinal tract disease. Am. J. Vet. Res., 52: 1565-1569.
33. Mossmann, T., 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods, 65: 55-63.
34. Neese, L.W., Standing, I.E., Olson, E.J., Castro, M. and Limper, A.H., 1994. Vitronectin, fibronectin, and gp120 antibody enhance macrophage release of TNF-α in response to Pneumocystis carinii. J. Immunol., 152: 4549-4556.
35. Osborn, L., Kinkel, S. and Nabel, G.J., 1989. Tumor necrosis factor a and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of nuclear factor κB. Proc. Natl. Acad. Sci. USA, 86: 2336-2340.
36. Porterfield, J.S., 1986. Antibody-dependent enhancement of viral infectivity. Adv. Virus Res., 31: 335-355.
37. Probert, L., Keffer, J., Corbella, P., Cazlaris, H., Patsavoudi, E., Stephens, S., Kaslaris, E., Kioussis, D. and Kollias, G., 1993. Wasting, ischemia, and lymphoid abnormalities in mice expressing T cell-targeted human tumor necrosis factor transgenes. J. Immunol., 151: 1894-1906.
38. Rieckmann, P., Poli, G., Fox, C.H., Kehrl, J.H. and Fauci, A.S., 1991. Recombinant gp120 specifically enhances tumor necrosis factor-alpha production and 1 g secretion in B lymphocytes from HIV-infected individuals but not from seronegative donors. J. Immunol., 147: 2922-2927.
39. Rwambo, P.M., Issel, C.J., Hussain, K.A. and Montelaro, R.C., 1990a. In vitro isolation of a neutralization escape mutant of equine infectious anemia virus (EIAV). Arch. Virol., 111: 275-280.
40. Rwambo, P.M., Issel, C.J., Hussain, K.A. and Montelaro, R.C., 1990b. In vitro isolation of a neutralization escape mutant of equine infectious anemia virus (EIAV). Arch. Virol., 111: 275-280.
41. Seethanathan, P., Bottoms, G.D. and Schafer, K., 1990. Characterization of release of tumor necrosis factor, interleukin-1 and superoxide anion from equine white blood cells in response to endotoxin. Am. J. Vet. Res., 51: 1221-1225.
42. Sellon, D.C., 1993. Equine infectious Anemia, p. 321-336. In: J.L. Traub-Dagatz (Editor), The Veterinary Clinics of North America - 1993. W.B. Saunders Co., Philadelphia, PA. pp. 321-336.
43. Sentsui, H. and Kono, Y., 1987. Complement-mediated hemolysis of horse erythrocytes treated with equine infectious anemia virus. Arch. Virol., 95: 53-66.
44. Shakov, A.N., Collart, M.A., Vassalli, P., Nedospasov, S.A. and Jongeneel, V.C., 1990. κB-type enhancers are involved in lipopolysaccharide-mediated transcriptional activation of the tumor necrosis factor α gene in primary macrophages. J. Exp. Med., 171: 35-47.
45. Sokal, R.R. and Rohlf, F.J., 1981. Biometry. W.H. Freeman and Co. New York, USA, pp. 859.
46. Taverne, J., Sheikh, N., de Souza, J.B., Playfair, J.H.L., Probert, L. and Kollias, G., 1994. Anaemia and resistance to malaria in transgenic mice expressing human tumor necrosis factor. Immunology, 82: 397-403.
47. Tracey, K.J. and Cerami, A., 1993. Tumor necrosis factor, other cytokines and disease. Ann. Rev. Cell Biol., 9: 317-343.
48. Vassalli, P., 1992. The pathophysiology of tumor necrosis factor. Ann. Rev. Immunol., 10: 411-452.
49. Wang, S.Z.-S., Rushlow, K.E., Issel, C.J., Cook, R.F., Cook, S.J., Raabe, M.L., Chong, Y.-H, Costa, L. and Montelaro, R.C., 1994. Enhancement of EIAV replication and disease by immunization with a baculovirus-expressed recombinant envelope surface glycoprotein. Virology, 199: 247-251.
50. Wilson, A.G., di Giovine, F.S., Blakemore, A.I.F. and Duff, G.W., 1992. Hum. Mol. Genet., 1: 353.
51. Wilson, A.G., Gordon, C., di Giovine, F.S., de Vries, N., van der Putte, L.B.A., Emery, P. and Duff, G.W., 1994. A genetic association between systemic lupus erythematosus and tumor necrosis factor. Eur. J. Immunol., 24: 191-195.